Ritter Pharmaceuticals Inc (NASDAQ:RTTR) gapped up prior to trading on Monday . The stock had previously closed at $0.27, but opened at $0.29. Ritter Pharmaceuticals shares last traded at $0.31, with a volume of 2738034 shares changing hands.
A number of brokerages have recently issued reports on RTTR. Zacks Investment Research cut shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. ValuEngine raised shares of Ritter Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $2.10.
The company has a market capitalization of $15.12 and a price-to-earnings ratio of -0.26.
An institutional investor recently bought a new position in Ritter Pharmaceuticals stock. Susquehanna International Group LLP bought a new stake in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned 4.49% of Ritter Pharmaceuticals as of its most recent filing with the SEC. Institutional investors own 20.34% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Ritter Pharmaceuticals (RTTR) Shares Gap Up to $0.29” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/03/12/ritter-pharmaceuticals-rttr-shares-gap-up-to-0-29.html.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.